All In Biotech

Drug Trial Radar · NCT05342636

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A.

Last checked: Nov 20, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Jul 27, 2022

Primary completion

Dec 5, 2025

Study completion Dec 5, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 22, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase I/II multicenter, open-label umbrella platform study that will evaluate the safety and efficacy of investigational agents with pembrolizumab, plus chemotherapy or lenvatinib, for the treatment of participants with advanced esophageal cancer who have failed 1 prior line of therapy and have not been previously exposed to programmed cell death 1 protein (PD-1)/ programmed cell death ligand 1 (PD-L1) based treatment. With protocol amendment 5 (effective: 17-November-2023), enrollment in study arms "Pembrolizumab plus MK-4830 plus Chemotherapy" and "Pembrolizumab plus MK-4830 plus lenvatinib" is discontinued.

Conditions

  • Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

  • PembrolizumabBiological

    200 mg administered via intravenous (IV) infusion every 3 weeks (Q3W)

  • Coformulation favezelimab/pembrolizumabBiological

    800 mg favezelimab + 200 mg pembrolizumab administered via IV infusion on day 1 and then Q3W

  • MK-4830Biological

    800 mg administered via IV infusion Q3W

  • LenvatinibDrug

    20 mg administered via oral capsules each day

  • IrinotecanDrug

    180 mg/m\^2 administered via IV infusion on day 1 of every 14-day cycle.

  • PaclitaxelDrug

    80-100 mg/m\^2 administered via IV infusion on Days 1, 8 and 15 of every 28 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing a Dose-limiting Toxicity (DLT) During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
  2. Number of Participants Experiencing an Adverse Event (AE) During Safety Lead-in PhaseTime frame: Up to approximately 3 Weeks
  3. Number of Participants Who Discontinue Study Treatment Due to an AE During Safety Lead-in PhaseTime frame: Up to approximately 3 weeks
  4. Objective Response Rate (ORR)Time frame: Up to approximately 40 months

Locations

46 sites in 13 countries. Site status is shown where the registry gives one.

  • Liga Norte Riograndense Contra o Câncer ( Site 2303)

    Natal, Rio Grande do Norte, Brazil

  • Hospital Nossa Senhora da Conceição ( Site 2301)

    Porto Alegre, Rio Grande do Sul, Brazil

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 2300)

    São Paulo, São Paulo, Brazil

  • FALP-UIDO ( Site 2400)

    Santiago, Region M. de Santiago, Chile

  • Clínica las Condes ( Site 2403)

    Santiago, Region M. de Santiago, Chile

  • Centre Hospitalier Régional Universitaire de Brest - Hôpital Morvan ( Site 1104)

    Brest, Finistere, France

  • Hopital Claude Huriez - CHU de Lille ( Site 1100)

    Lille, Nord, France

  • Pitie Salpetriere University Hospital ( Site 1102)

    Paris, Orne, France

  • Charité Campus Virchow-Klinikum-Klinik Hämatologie Onkologie Tumorimmunologie ( Site 2804)

    Berlin, Germany

  • Institut für Klinisch Onkologische Forschung-Klink für Onkologie und Hämatologie ( Site 2801)

    Frankfurt am Main, Hesse, Germany

  • Universitaetsklinikum Duesseldorf ( Site 2802)

    Düsseldorf, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 2806)

    Dresden, Saxony, Germany

  • Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (

    Milan, Italy

  • Istituto Oncologico Veneto IRCCS ( Site 1205)

    Padova, Italy

  • Ospedale San Raffaele-Oncologia Medica ( Site 1206)

    Milan, Lombardy, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1200)

    Milan, Lombardy, Italy

  • Aichi Cancer Center Hospital ( Site 1702)

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East ( Site 1701)

    Kashiwa, Chiba, Japan

  • Saitama Prefectural Cancer Center ( Site 1703)

    Ina-machi, Saitama, Japan

  • Shizuoka Cancer Center ( Site 1704)

    Nagaizumi-cho,Sunto-gun, Shizuoka, Japan

  • National Cancer Center Hospital ( Site 1700)

    Chuo-ku, Tokyo, Japan

  • Oslo universitetssykehus, Radiumhospitalet ( Site 2501)

    Oslo, Norway

  • National University Hospital ( Site 1800)

    Singapore, South West, Singapore

  • Asan Medical Center-Department of Oncology ( Site 1901)

    Seoul, South Korea

  • Samsung Medical Center-Division of Hematology/Oncology ( Site 1900)

    Seoul, South Korea

  • Hôpitaux Universitaires de Genève (HUG) ( Site 2702)

    Geneva, Canton of Geneva, Switzerland

  • Kantonsspital Graubünden-Medizin ( Site 2700)

    Chur, Kanton Graubünden, Switzerland

  • China Medical University Hospital ( Site 2007)

    Taichung, Taiwan

  • Taichung Veterans General Hospital-Radiation Oncology ( Site 2008)

    Taichung, Taiwan

  • National Cheng Kung University Hospital ( Site 2001)

    Tainan, Taiwan

  • National Taiwan University Hospital ( Site 2000)

    Taipei, Taiwan

  • Taipei Veterans General Hospital ( Site 2005)

    Taipei, Taiwan

  • Chang Gung Medical Foundation-Linkou Branch ( Site 2006)

    Taoyuan, Taiwan

  • Chang Gung Memorial Hospital at Kaohsiung ( Site 2003)

    Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan

  • Chulalongkorn University ( Site 2104)

    Bangkok, Bangkok, Thailand

  • Faculty of Medicine Siriraj Hospital ( Site 2102)

    Bangkok, Bangkok, Thailand

  • Songklanagarind hospital ( Site 2105)

    Hat Yai, Changwat Songkhla, Thailand

  • Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 1417)

    Adana, Turkey (Türkiye)

  • Hacettepe Universite Hastaneleri-oncology hospital ( Site 1402)

    Ankara, Turkey (Türkiye)

  • Memorial Ankara Hastanesi-Medical Oncology ( Site 1408)

    Ankara, Turkey (Türkiye)

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.